Physician profile

Patrick C Kilduff

Internal Medicine · Wilkes Barre, PA

NPI 1003857186

$1,103.92

in general payments reported to CMS, 2019-2025

17 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Amgen INC. $300.53 2019-2020
Novo Nordisk INC $182.01 2019-2020
Boehringer Ingelheim Pharmaceuticals, INC. $141.90 2019-2020
Janssen Pharmaceuticals, INC $94.69 2022
Amarin Pharma, INC. $69.64 2019
Lilly USA, LLC $59.01 2019
Pfizer INC. $39.51 2019
Merck Sharp & Dohme LLC $38.77 2019
Sanofi-Aventis U.S. LLC $31.85 2019
Kowa Pharmaceuticals America, INC. $29.99 2019
Teva Pharmaceuticals USA, INC. $26.67 2019
Takeda Pharmaceuticals U.S.A., INC. $21.00 2019
Astrazeneca Pharmaceuticals Lp $17.01 2019
Glaxosmithkline, LLC. $13.87 2019
E.R. Squibb & Sons, L.L.C. $13.05 2019
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Allergan, INC. $12.42 2019
Daiichi Sankyo INC. $12.00 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Patrick C Kilduff

$1,103.92

in general payments reported 2019-2025

Years
2019-2022
Top company
Amgen INC.

https://glasscript.com/doctor/45413/patrick-c-kilduff

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.